# A Prospective Cohort to Study the Effect of Temozolomide on IDH Mutational Low Grade Gliomas

> **NCT02209428** · PHASE2 · UNKNOWN · sponsor: **Huashan Hospital** · enrollment: 54 (actual)

## Conditions studied

- Astrocytoma
- Oligodendroglioma
- Oligoastrocytoma

## Interventions

- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT02209428
- **Lead sponsor:** Huashan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-06
- **Primary completion:** 2019-04
- **Final completion:** 2019-05
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2019-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02209428

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02209428, "A Prospective Cohort to Study the Effect of Temozolomide on IDH Mutational Low Grade Gliomas". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02209428. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*